A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism.

A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism. - A multicenter clinical study to test the efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012273

Enrollment

Registered

2013-11-12

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical amnitotic fluid embolism

Interventions

From the date of permission to March 31st, 2006, Bolus iv dose of C1 inactivator will be administered to patins with Amniotic fluid embolism. The dosage is 1000times per one time. It is allowed to gi

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with Amniotic fluid embolism who full fill the criteria shown as follows. #1. Symptom should occur within 12 hrs after delivery. #2. Massive uterine bleeding of unknown etiology that occurred within 2hrs after delivery. #3. Disseminated intravascular coagulation(DIC)

Exclusion criteria

Exclusion criteria: Patients who are anaphylactic to C1-inhibitor drug.

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptom Improvement of laboratory data	—

Countries

Japan

Contacts

Public ContactOsato Kazuhiro

Mie University hospital Obstetrics and gynecology

osati-kazu@clin.medic.mie-u.ac.jp0592325111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026